Biotest AG is aiming to further expand its already strong position on the Russian market through a distribution agreement with the Merz Pharma GmbH & Co. KGaA. Both companies identify significant synergy potential from their cooperation. Merz Pharma will sell the products of Intratect(R), Pentaglobin(R), Neohepatect(R), Neocytotect(R) and Albiomin(R) through its Russian subsidiary. The distribution agreement has come into effect as of January 1, 2013. Biotest AG will continue to be represented in Russia through its Representative Office. Its core activities will comprise drugs approvals, pharmacovigilance and scientific medical advice. Biotest will continue to directly offer its Factor VIII product Haemoctin(R) in state tenders through a Russian distributor. This agreement aims to utilise synergies with a company operating in Russia, to market its products (except Haemoctin(R)) on a targeted basis, and to significantly enhance its long-term market position.

Biotest AG also announced that it could win one of the most significant Vianex S. A to take over registration and distribution for Biotest in Greece. In order to show continuity towards its customers and also to take responsibility for the Biotest employees, Vianex has taken over all available employees of Biotest Hellas. Vianex will start selling its products as soon as the registration is transferred.